DK1470107T3 - Fluor-substituerede cykloalkanoindoler og anvendelser heraf som prostaglandin D2-receptorantagonister - Google Patents

Fluor-substituerede cykloalkanoindoler og anvendelser heraf som prostaglandin D2-receptorantagonister

Info

Publication number
DK1470107T3
DK1470107T3 DK03700740T DK03700740T DK1470107T3 DK 1470107 T3 DK1470107 T3 DK 1470107T3 DK 03700740 T DK03700740 T DK 03700740T DK 03700740 T DK03700740 T DK 03700740T DK 1470107 T3 DK1470107 T3 DK 1470107T3
Authority
DK
Denmark
Prior art keywords
prostaglandin
fluoro
applications
receptor antagonists
cycloalkanoindoles
Prior art date
Application number
DK03700740T
Other languages
Danish (da)
English (en)
Inventor
Carl Berthelette
Lianhai Li
Claudio Sturino
Nicolas Lachance
Zhaoyin Wang
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Application granted granted Critical
Publication of DK1470107T3 publication Critical patent/DK1470107T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
DK03700740T 2002-01-24 2003-01-22 Fluor-substituerede cykloalkanoindoler og anvendelser heraf som prostaglandin D2-receptorantagonister DK1470107T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35138402P 2002-01-24 2002-01-24
PCT/CA2003/000084 WO2003062200A2 (en) 2002-01-24 2003-01-22 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Publications (1)

Publication Number Publication Date
DK1470107T3 true DK1470107T3 (da) 2009-03-09

Family

ID=27613492

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03700740T DK1470107T3 (da) 2002-01-24 2003-01-22 Fluor-substituerede cykloalkanoindoler og anvendelser heraf som prostaglandin D2-receptorantagonister
DK08105552.7T DK2045241T3 (da) 2002-01-24 2003-01-22 Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08105552.7T DK2045241T3 (da) 2002-01-24 2003-01-22 Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister

Country Status (39)

Country Link
US (6) US20030158246A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2295409B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP4008885B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100859230B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN101092388A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR038136A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE414690T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003202343B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0307050A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2471952C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1108841T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE122009000022I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1470107T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2003000566A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA006134B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP045203A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG24978A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2316717T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR09C0010I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20074078B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20040665B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL162825A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (2) IS2633B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO2481B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91534I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04007167A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY137040A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300377I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO327322B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ533786A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20030982A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL208527B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2045241E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS20100338A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1470107T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI259080B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA75520C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003062200A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200404999B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (en) * 2003-05-16 2004-12-02 Merck & Co., Inc. Enzymatic preparation of chiral indole esters
CA2526013A1 (en) * 2003-05-20 2004-12-02 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
JP4769718B2 (ja) * 2003-08-07 2011-09-07 メルク シャープ エンド ドーム リミテッド アルツハイマー病及び関連症状の治療
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
ATE384046T1 (de) * 2004-04-02 2008-02-15 Merck & Co Inc Verfahren zur asymmetrischen hydrierung, das sich für die herstellung von cycloalkanindolderivaten eignet
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
US20070299122A1 (en) * 2004-11-08 2007-12-27 Tobert Jonathan A Method of Treating Pathological Blushing
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006068162A1 (ja) * 2004-12-24 2006-06-29 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の治療剤
PT1833791E (pt) 2004-12-27 2011-10-19 Actelion Pharmaceuticals Ltd Derivados de 2,3,4,9-tetra-hidro-1h-carbazol como antgonistas do receptor crth2
JP2008530250A (ja) * 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
CA2603757A1 (en) * 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
WO2007010965A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Pgd2受容体アンタゴニスト活性を有するアザインドール酸誘導体
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
PL2037967T3 (pl) 2006-06-16 2017-07-31 The Trustees Of The University Of Pennsylvania Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego
JP5220013B2 (ja) 2006-08-07 2013-06-26 アクテリオン ファーマシューティカルズ リミテッド (3−アミノ−1,2,3,4−テトラヒドロ−9h−カルバゾール−9−イル)−酢酸誘導体
WO2008097535A2 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
CN102224154A (zh) * 2008-09-25 2011-10-19 默克弗罗斯特加拿大有限公司 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) * 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
US8882678B2 (en) 2009-03-13 2014-11-11 Atrium Medical Corporation Pleural drainage system and method of use
PL2558447T3 (pl) 2010-03-22 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2
HRP20161235T1 (hr) 2011-04-14 2016-11-04 Actelion Pharmaceuticals Ltd. Derivati 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido(1,2-a)indol-octene kiseline i njihova uporaba kao modulatori receptora prostaglandina d2
JP5841361B2 (ja) * 2011-06-29 2016-01-13 壽製薬株式会社 三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) * 2012-03-28 2015-01-21 中国计量学院 合成分离拉洛皮兰及其类似物的方法
FR3000399B1 (fr) * 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
LT3119779T (lt) 2014-03-17 2018-09-10 Idorsia Pharmaceuticals Ltd Azaindolo acto rūgšties dariniai ir jų panaudojimas kaip prostaglandino d2 receptoriaus moduliatorių
TW201620909A (zh) 2014-03-18 2016-06-16 艾克泰聯製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素d2受體調節劑之用途
WO2016128565A1 (en) 2015-02-13 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
HK1255148A1 (zh) 2015-09-15 2019-08-09 Idorsia Pharmaceuticals Ltd 结晶形式
KR102465211B1 (ko) 2018-03-19 2022-11-10 미쯔이가가꾸가부시끼가이샤 표시 소자용 밀봉재 및 그의 경화물, 유기 el 소자용 프레임 밀봉재, 그리고 유기 el 소자용 면 밀봉재

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3768097D1 (de) 1986-01-23 1991-04-04 Merck Frosst Canada Inc Tetrahydrocarbazol-1-alkansaeuren.
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
EP0769958B1 (en) 1994-07-11 2003-04-16 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
EA000987B1 (ru) 1995-06-21 2000-08-28 Сионоги Энд Ко., Лтд. Бициклические аминопроизводные и содержащие их антагонисты pgd2
JPH11508583A (ja) 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
BR9714016A (pt) 1996-12-13 2000-02-29 Shionogi & Co Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos
DE69925270T2 (de) 1998-06-03 2006-02-23 Shionogi & Co., Ltd. Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Also Published As

Publication number Publication date
KR20070056166A (ko) 2007-05-31
CN101092388A (zh) 2007-12-26
RS62404A (en) 2006-12-15
EP2295409A1 (en) 2011-03-16
US20030158246A1 (en) 2003-08-21
DK2045241T3 (da) 2012-10-15
EP2045241B1 (en) 2012-07-04
JP4008885B2 (ja) 2007-11-14
MY137040A (en) 2008-12-31
IL162825A (en) 2010-12-30
NO2009013I1 (no) 2009-06-29
EP1470107B1 (en) 2008-11-19
ES2391747T3 (es) 2012-11-29
US20100081696A1 (en) 2010-04-01
GEP20074078B (en) 2007-03-26
EA200400971A1 (ru) 2004-12-30
PT1470107E (pt) 2009-01-30
FR09C0010I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-12-18
US20120115921A1 (en) 2012-05-10
HRP20040665A2 (en) 2005-04-30
JP2005518413A (ja) 2005-06-23
IL188844A0 (en) 2009-02-11
IS7329A (is) 2004-06-21
LU91534I2 (fr) 2009-04-27
NO2009013I2 (no) 2012-08-27
PL208527B1 (pl) 2011-05-31
RS20100338A (en) 2011-06-30
EP2045241A1 (en) 2009-04-08
CA2471952A1 (en) 2003-07-31
IS8887A (is) 2010-03-01
DE122009000022I1 (de) 2009-08-06
EP2295409B1 (en) 2014-07-02
NZ533786A (en) 2006-11-30
SI2045241T1 (sl) 2012-11-30
CY2009004I2 (el) 2009-11-04
RS51672B (en) 2011-10-31
CY1113330T1 (el) 2016-06-22
NL300377I2 (nl) 2009-08-03
TW200302090A (en) 2003-08-01
US7317036B2 (en) 2008-01-08
US7618994B2 (en) 2009-11-17
NO20043536L (no) 2004-08-24
BR0307050A (pt) 2004-10-26
EA006134B1 (ru) 2005-10-27
WO2003062200A2 (en) 2003-07-31
EP1470107A2 (en) 2004-10-27
PT2045241E (pt) 2012-09-26
US20080033028A1 (en) 2008-02-07
PL370427A1 (en) 2005-05-30
AR038136A1 (es) 2004-12-29
SI1470107T1 (sl) 2009-04-30
CN1902176A (zh) 2007-01-24
CY1108841T1 (el) 2011-04-06
EG24978A (en) 2011-04-03
NO327322B1 (no) 2009-06-08
PE20030982A1 (es) 2003-11-19
KR100859230B1 (ko) 2008-09-18
HRP20040665B1 (en) 2012-11-30
IL162825A0 (en) 2005-11-20
DE60324767D1 (de) 2009-01-02
NO20071193L (no) 2004-08-24
TWI259080B (en) 2006-08-01
CN101851191A (zh) 2010-10-06
AU2003202343B2 (en) 2007-07-12
JP2007186521A (ja) 2007-07-26
MXPA04007167A (es) 2004-10-29
WO2003062200A3 (en) 2003-12-04
ATE414690T1 (de) 2008-12-15
UA75520C2 (en) 2006-04-17
AU2003202343C1 (en) 2003-09-02
US20060069148A1 (en) 2006-03-30
NL300377I1 (nl) 2009-05-06
CA2471952C (en) 2008-04-01
ES2316717T3 (es) 2009-04-16
FR09C0010I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-04-17
ZA200404999B (en) 2006-05-31
CY2009004I1 (el) 2009-11-04
ECSP045203A (es) 2004-09-28
JO2481B1 (en) 2009-01-20
US20050124680A1 (en) 2005-06-09
DOP2003000566A (es) 2003-09-15
KR20040075109A (ko) 2004-08-26
IS2633B (is) 2010-06-15

Similar Documents

Publication Publication Date Title
DK1470107T3 (da) Fluor-substituerede cykloalkanoindoler og anvendelser heraf som prostaglandin D2-receptorantagonister
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK1448535T3 (da) Benzamid og heteroarylamid som P2X7-receptor antagonister
ATE416168T1 (de) Modulatoren des vanilloidrezeptors
NO20043803L (no) Substituerte amider som er aktive i cannabinoid 1-reseptoren
NL1025148A1 (nl) Benzamideremmers van de P2X7-receptor.
NO20044588L (no) Nye forbindelser
IS7801A (is) Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla
ATE380544T1 (de) Umhüllte feste darreichungsform
DE60308953D1 (de) Nähfadenanker
DE60320067D1 (de) Nähfadenankersystem
DK1523493T3 (da) Nye tubulysinanaloge
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
IS7715A (is) Nýjar lyfjasamsetningar úr módafíníl
DK1487778T3 (da) Substituerede 4 aminocyclohexanoler
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
DE60302087D1 (de) Gleichlaufgelenk
FI20021934L (fi) Liittopalkki
NO20044098L (no) Nye forbindelser
DE10311703B4 (de) Fahnenmast
FR2847624B1 (fr) Joint spherique
FR2843451B1 (fr) Fronde du type lance-pierres
NO20055725D0 (no) Glutamatreseptorantagonister som neurobeskyttende midler
FI20020049A0 (fi) Sõhk÷keskusrakenne